Filing Details

Accession Number:
0000899243-20-030622
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-09 16:05:09
Reporting Period:
2020-11-06
Accepted Time:
2020-11-09 16:05:09
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
31791 Perkinelmer Inc PKI Laboratory Analytical Instruments (3826) 042052042
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1519218 Andrew Okun 940 Winter Street
Waltham MA 02451
Please See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-06 6,107 $81.29 16,417 No 4 M Direct
Common Stock Disposition 2020-11-06 6,107 $140.14 10,310 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock NQ Stock Option (right to buy) Disposition 2020-11-06 6,107 $0.00 6,107 $81.29
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
3,054 2025-01-30 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 8 Indirect By 401(K)
Footnotes
  1. The Exercise Price included on the Form 4 filed on February 1, 2018 for the Reporting Person was incorrectly reported due to administrative error.
  2. The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by Mr. Okun on September 3, 2020.
  3. The price reported represents a weighted average sale price of shares sold in multiple transactions at prices ranging from $140.05 to $140.28. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
  4. This option became exercisable in three equal annual installments beginning on January 30, 2019, which was the first anniversary of the date on which the option was granted.